These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1366 related articles for article (PubMed ID: 30395986)
1. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia. Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491 [TBL] [Abstract][Full Text] [Related]
5. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821 [TBL] [Abstract][Full Text] [Related]
6. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
7. Activity of Cefiderocol Against Iregui A; Khan Z; Landman D; Quale J Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [TBL] [Abstract][Full Text] [Related]